About IE

Mission

To accelerate the translation of ATP-Bio innovations into real-world impact by fostering a dynamic ecosystem of researchers, entrepreneurs, and industry partners.

Vision

A thriving biopreservation innovation network that bridges discovery and deployment—advancing technologies that benefit health, sustainability, and society.

Strategy

Drive early-stage commercialization by increasing technology readiness, strengthening partnerships, and expanding entrepreneurial support.

Goals

The Strategic Priorities of the Engineering Workforce Development Program are tied to the above strategy.

  • Pair ITAs with industry advisors
  • Conduct commercialization readiness assessments
  • Engage 40+ industrial and innovation members
  • Expand collaboration to reduce commercialization risk
  • Grow the CRYOFOUNDRY incubator
  • Deliver i-Corps-based entrepreneurial training
  • Connect start-ups to SBIRs and private capital

INNOVATION

Regenerative medicine, aquaculture, and other industries related to ATP-Bio are worth over $300B globally and are predicted to grow substantially by 2027.

Global Market Size ($B) in 2020
Aquaculture
Solid Organs & Tissues
Regenerative Medicine & Cell Therapy
MPS (”Organs-on-Chip”)
Global Market CAGR (%)

Solid Organs / Tissues and Aquaculture markets are larger, more mature,with less growth. They are ripe for disruption from new technologies such as ATP-Bio. Regenerative medicine and cell therapies and MPS are emerging markets, with huge growth potential, and where ATP-Bio technologies can have a dramatic impact on that growth. ATP-Bio technologies are poised to improve all four of these markets, and thereby save more lives and feed more people.